Of note, beside in the over 65-year-old, EBF1low, MYO6low and CALRhigh signature expression is able to dichotomize the response to R-CHOP treatment in under 65-year-old DLBCL patients (Figure 4B; Supplementary Figure S4B). Here, DDIT3 is linked to diffuse large B-cell lymphoma.